Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tara C Mitchell

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Nature Immunology|July 28, 2022
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccineRamin Sedaghat Herati, David A Knorr, Laura A Vella, et al.
American Journal of Rhinology & Allergy|January 9, 2025
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal MelanomaRijul S Kshirsagar, Jacob G Eide, Jacob Harris, et al.
Molecular Cell|February 8, 2020
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in MelanomaMarie R Webster, Mitchell E Fane, Gretchen M Alicea, et al.
Molecular Cell|December 15, 2019
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in MelanomaMarie R Webster, Mitchell E Fane, Gretchen M Alicea, et al.
Nature|August 10, 2018
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 responseGang Chen, Alexander C Huang, Wei Zhang, et al.
Cancer Cell|August 30, 2024
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cellsKevin Wang, Paulina Coutifaris, David Brocks, et al.
Nature Medicine|February 27, 2019
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaAlexander C Huang, Robert J Orlowski, Xiaowei Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant MelanomaGao Zhang, Lawrence W Wu, Ilgen Mender, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Nature Immunology|July 28, 2022
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccineRamin Sedaghat Herati, David A Knorr, Laura A Vella, et al.
American Journal of Rhinology & Allergy|January 9, 2025
Outcomes of Immunotherapy Treatment in Sinonasal Mucosal MelanomaRijul S Kshirsagar, Jacob G Eide, Jacob Harris, et al.
Molecular Cell|February 8, 2020
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in MelanomaMarie R Webster, Mitchell E Fane, Gretchen M Alicea, et al.
Molecular Cell|December 15, 2019
Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in MelanomaMarie R Webster, Mitchell E Fane, Gretchen M Alicea, et al.
Nature|August 10, 2018
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 responseGang Chen, Alexander C Huang, Wei Zhang, et al.
Cancer Cell|August 30, 2024
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cellsKevin Wang, Paulina Coutifaris, David Brocks, et al.
Nature Medicine|February 27, 2019
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanomaAlexander C Huang, Robert J Orlowski, Xiaowei Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant MelanomaGao Zhang, Lawrence W Wu, Ilgen Mender, et al.
Cell Reports|June 3, 2026
Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterationsKonstantinos Tsingas, Monzy Thomas, McKenna Reale, et al.
Cancer Research|August 31, 2021
Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy ResistanceJianglan Liu, Vito W Rebecca, Andrew V Kossenkov, et al.
Pageof 7